Powered by

INNATE PHARMA reports its consolidated financial results for the year ended December 31, 2016

Mar 6, 2017 - GlobeNewswire
Board and Executive Moves - Financial Results

2016: Operational progress and robust financial position for further growth

Cash, cash equivalents and financial instruments[*] amounted to ‚¬230.7m (million euros) as of December 31, 2016 Operating expenses amounted to ‚¬58.2m (‚¬35.9m in 2015); increase driven by continued investment in its portfolio of drug candidates Revenue and other income amounted to ‚¬65.7m (‚¬25.1m in 2015), including $15m (‚¬13.8m) milestone payment from Bristol-Myers Squibb related to prog

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox